Aptevo Therapeutics Inc. | Mutual Funds
Mutual Funds that own Aptevo Therapeutics Inc.
Vanguard Total Stock Market Index Fund
446,531
1.98%
0
0%
07/31/2018
DFA US Small Cap Portfolio
248,923
1.1%
37,771
0.01%
04/30/2018
Vanguard Extended Market Index Fund
232,945
1.03%
0
0%
07/31/2018
DFA US Targeted Value Portfolio
218,700
0.97%
28,463
0.01%
04/30/2018
DFA US Micro Cap Portfolio
142,625
0.63%
1,800
0.01%
04/30/2018
Tredje AP Fonden
138,700
0.61%
0
0%
06/30/2017
DFA Tax Managed US Targeted Value Portfolio
94,180
0.42%
21,579
0.01%
04/30/2018
DFA Tax Managed US Small Cap Portfolio
74,897
0.33%
6,459
0.01%
04/30/2018
Fidelity Spartan Extended Market Index Fund
62,747
0.28%
0
0%
07/31/2018
DFA US Core Equity 2 Portfolio
52,865
0.23%
0
0%
04/30/2018
| Address |
2401 4th Avenue
Seattle Washington 98121
United States
|
|
Employees
|
- |
| Website |
http://aptevotherapeutics.com |
| Updated |
07/08/2019 |
| Aptevo Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, commercialization and sale of novel oncology and hematology therapeutics. Its pipeline includes Otlertuzumab, APVO414, APVO436, ROR1 Candidate, and ALG. APV-527. |
